Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2026 | ZiPUP: 89Zirconium-labelled girentuximab PET in patients with urothelial cancer

Dickon Hayne • 13 Mar 2026
EAU 2026
Bladder Cancer Genitourinary Cancer
ZiPUP

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the ZiPUP study (NCT05046665), a new PET scan using zirconium girentuximab, for staging urothelial cancer. Dr Hayne highlights that while the study showed zirconium girentuximab to be safe and feasible, FDG PET was better at identifying metastatic sites, although zirconium girentuximab may have potential as a theranostic agent. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Dickon Hayne

CAIX expression in urothelial cancer
0:46
CAIX expression in urothelial cancer
Dickon Hayne • 13 Mar 2026
ANZUP 1301: effects on urinary symptoms and other aspects of HRQL
2:38
ANZUP 1301: effects on urinary symptoms and other aspects of HRQL
Dickon Hayne • 15 Mar 2026
G-DISCO: synchronous gemcitabine and docetaxel as an intravesical therapy for high-risk NMIBC
1:51
G-DISCO: synchronous gemcitabine and docetaxel as an intravesical therapy for high-risk NMIBC
Dickon Hayne • 15 Mar 2026
ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer
1:03
ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer
Dickon Hayne • 31 May 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals